Volume 1.13 | Apr 13

Hematopoiesis News 1.13, April 13, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

China Scientists Show How Arsenic Treats Blood Cancer
Scientists in China have demonstrated how arsenic destroys deadly blood cancer by targeting and killing specific proteins that keep the cancer alive. [Press release from Reuters discussing online prepublication in Science]

HEMA  
Become an expert at colony identification
Hematopoietic Progenitor Assay Training Course
by STEMCELL Technologies
 
 
REGISTER HERE STEMCELL Technologies Inc
 


SCIENCE NEWS

Supplement Your Stem Cells
Recent research suggests that a commercially-available supplement can increase the blood circulation of hematopoietic stem cells, which can give rise to all blood cells, and endothelial progenitor cells. [Press release from EurekAlert! discussing online prepublication in Journal of Translational Medicine]

MethoCult® Express: Request A Sample  
Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express
by STEMCELL Technologies
 
 
REQUEST A SAMPLE STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS

LABORATORY RESEARCH 

Arsenic Trioxide Controls the Fate of the PML-RAR(Alpha) Oncoprotein by Directly Binding PML
The identification of PML as a direct target of arsenic trioxide provides new insights into the drug’s mechanism of action and its specificity for acute promyelocytic leukemia. [Science]

CYT387, A Novel JAK2 Inhibitor, Induces Hematologic Responses and Normalizes Inflammatory Cytokines in Murine Myeloproliferative Neoplasms
Researchers have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and TYK2 at low nanomolar concentrations, with few additional targets. [Blood]

Lentiviral Gene Therapy of Murine Hematopoietic Stem Cells Ameliorates the Pompe Disease Phenotype
Based on the prominent and sustained therapeutic efficacy without adverse events in mice, researchers conclude that ex vivo hematopoietic stem cell gene therapy is a treatment option worthwhile to pursue. [Blood]

Nrf2 Responses and the Therapeutic Selectivity of Electrophilic Compounds in Chronic Lymphocytic Leukemia
These experiments document the presence of nuclear factor erythroid 2-related factor 2 (Nrf2) signaling in human chronic lymphocytic leukemia and suggest that altered Nrf2 responses may contribute to the observed selective cytotoxicity of electrophilic compounds in this disease. [Proc Natl Acad Sci U S A]

POU4F1 is Associated with t(8;21) Acute Myeloid Leukemia and Contributes Directly to its Unique Transcriptional Signature

In this study, researchers showed that POU4F1 overexpression is highly correlated with, but not caused by, AML1/ETO fusion protein. [Leukemia]

Elevated PIN1 Expression by C/EBP(Alpha)-p30 Blocks C/EBP(Alpha)-Induced Granulocytic Differentiation Through c-Jun in AML
Overexpression of PIN1 in myeloid cells leads to block of granulocyte differentiation. Researchers also show that PIN1 increases the stability of the c-Jun protein by inhibiting c-Jun ubiquitination, and c-Jun blocks granulocyte differentiation mediated by C/EBP(Alpha).  [Leukemia]

CLINICAL RESEARCH

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia. These differences could result from variable therapy adherence. [J Clin Oncol]

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
Treatment options for older patients with acute myeloid leukemia who are not considered suitable for intensive chemotherapy are limited. Researchers assessed the second-generation purine nucleoside analog, clofarabine, in two similar phase II studies in this group of patients. [J Clin Oncol]

Molecular Alterations of the IDH1 Gene in AML: A Children’s Oncology Group and Southwest Oncology Group Study
Researchers studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult acute myeloid leukemia (AML). [Leukemia]

Nutraceutical Augmentation of Circulating Endothelial Progenitor Cells and Hematopoietic Stem Cells in Human Subjects
Research data suggest Stem-Kine supplementation may be useful as a stimulator of reparative processes associated with mobilization of hematopoietic and endothelial progenitors. [J Transl Med]

INDUSTRY NEWS

Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics
Fate Therapeutics, Inc. announced a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. [Fate Therapeutics, Inc. Press Release]

CareFusion to Acquire IV Innovator Medegen for $225 Million
CareFusion Corp. announced an agreement to acquire Medegen, a leading innovator in clinically differentiated needleless access valves and administration sets that deliver intravenous (IV) medication to patients, for $225 million in cash. [CareFusion Corp. Press Release]

Haemonetics Sees 2010 Profit at Top of Forecast
Blood collection and processing systems maker Haemonetics Inc. said it now expects full-year earnings will come in at the high end of its prior forecast, excluding costs related to its recent purchase of Global Med Technologies Inc. [BusinessWeek]

Virus Leads Canadian Blood Service to Ban Certain Donors
An AIDS-like virus that has been linked to chronic fatigue syndrome is causing Canadian blood officials to ban anyone who has suffered from the ailment from making donations. [Toronto Star]

Test Data for Blood Product Systematically Fabricated
A subsidiary of Mitsubishi Tanabe Pharma Corp. systematically falsified test data on allergic reactions during the development of one of its blood products, sources familiar with the matter said. [Japan Times]

National Effort Scrutinizes Costly Blood Transfusion Complications
One area this national project is focusing on is an adverse event that occurs when a transfused patient suffers a minor or severe reaction because they were allergic to white cells that were included in red cell or plasma transfusions. They can cause fever, chilling, shaking, unconsciousness, and other symptoms that require days of extra hospital stays, and, of course, more expense to the healthcare system. [HeathLeadersMedia]

Cytomedix Finds Potential New Revenue Stream
Cytomedix Inc., which lost about 89 percent of its revenue late last year when licensing agreements came to an end, has bought a new product line that generated $5 million in sales last year. [Washington Business Journal]

Blood Banks Fight to Keep Financial Records Private
The move by a state senator to force Florida’s blood banks to open their financial books to the public is running into opposition from the institutions he seeks to regulate. [Orlando Sentinel]


POLICY NEWS

University of Chicago Physician Named to Presidential Commission for the Study of Bioethical Issues
Daniel Sulmasy, MD, PhD, the Kilbride-Clinton Professor of Medicine and Ethics in the Department of Medicine and the Divinity School, and Associate Director of the MacLean Center for Clinical Medical Ethics at the University of Chicago, has been named to the Presidential Commission for the Study of Bioethical Issues. [Presidential Commission for the Study of Bioethical Issues, United States]

National Human Genome Research Institute Names New Chief of Genome Technology Branch
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, has named Lawrence C. Brody, Ph.D., as the new chief of its Genome Technology Branch, the largest of seven branches in the NHGRI Division of Intramural Research. [National Institutes of Health, United States]

Minor Use Minor Species Development of Drugs; Research Project Grant (R01) (RFA-FD-10-001) [National Institutes of Health, United States]

Bioengineering Nanotechnology Initiative [STTR (R41/R42)] (PA-10-149) [National Institutes of Health, United States]

Bioengineering Nanotechnology Initiative [SBIR (R43/R44)] (PA-10-150) [National Institutes of Health, United States]

Clinical Investigator Status (Biologics) [Food and Drug Administration, United States]

Background on Study Results of U.S. Academic Researchers [Food and Drug Administration, United States]

May 7, 2010: Vaccines and Related Biological Products Advisory Committee Meeting Announcement [Food and Drug Administration, United States]

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Secretary Sebelius Announces Five New Health and Human Services Regional Directors [Department of Health & Human Services, United States]

EVENTS

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

16th International Society for Cellular Therapy (ISCT) Meeting
May 23-26, 2010
Philadelphia, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.




Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

 

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us